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MICROBES, IMMUNITY, AND DISEASE 
VIEWPOINT 
The Search for Unrecognized Pathogens 
David A. Relman 
The distribution and diversity of microorganisms in the world are far 
greater than have been previously appreciated. Molecular, cultivation- 
independent methods have played a key role in this insight. To what 
extent do humans remain ignorant of microbial diversity within the human 
body and the settings in which microorganisms cause human disease? In 
addition to implicating microbial agents in nontraditional infectious dis- 
eases, the use of methods such as broad-range polymerase chain reaction, 
representational difference analysis, expression library screening, and host 
gene expression profiling may force a reassessment of the concepts of 
microbial disease causation. 
Within the world of cultivated bacteria, vi- 
ruses, and unicellular eukaryotes that inhabit 
the human body, the number and variety of 
relations between microbe and host are 
breathtaking. Yet, surveys of many terrestrial 
and aquatic ecosystems indicate that >99% 
of microorganisms resist cultivation in the 
laboratory and can only be identified or char- 
acterized with the use of molecular approach- 
es (1). We presume to know much about the 
ecosystem most intimately related to our very 
existence-the microbial world within the 
human body. Nearly all available information 
about the composition of the endogenous mi- 
croflora and the role of microorganisms in 
human disease has been based on laboratory 
cultivation. Are we as ill-informed about 
these human-associated segments of the mi- 
crobial world? We would expect this not to 
be the case, because such a large effort is 
dedicated to microbial identification once hu- 
mans develop clinical signs of infection. But, 
a number of observations suggest inadequa- 
cies in current diagnostic methods. The ensu- 
ing discussion describes alternative methods 
that have the potential to enhance the recog- 
nition and characterization of microbial dis- 
ease, as well as to change the way we view 
disease causation. 
The traditional diagnostic approach of iso- 
lating the etiologic agent or demonstrating a 
substantial change in antibody titer to a spe- 
cific pathogen requires some understanding 
of growth conditions or specific antigenic 
determinants. Yet, these requirements have 
limited our ability to recognize and identify 
microbial pathogens. Beginning with the 
work of Robert Koch in the late 19th century, 
generations of epidemiologists, clinicians, 
and pathologists have confronted the same 
obstacles in their quest to explain disease 
patterns that are reminiscent of infection. The 
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causes of Crohn's disease, ulcerative colitis, 
Wegener's granulomatosis, rheumatoid ar- 
thritis, tropical sprue, systemic lupus ery- 
thematosus, Kawasaki's disease, and other 
chronic diseases remain unknown despite dis- 
ease features that are suggestive of infectious 
etiology. 
Search Methods 
Relying on an infectious agent to "perform" 
in the laboratory for the purposes of detection 
and identification poses a number of potential 
pitfalls. Identification of infectious agents by 
phenotypic traits is insensitive, because we 
are largely ignorant of the environmental 
conditions required by some microorganisms 
for growth and, hence, are unable to replicate 
them in the laboratory. Phenotypic traits are 
also difficult to quantitate, and they can be 
misleading. In contrast, genotypic traits gen- 
erally provide reliable and quantifiable infor- 
mation for the identification and characteriza- 
tion of infectious agents. Moreover, genotyp- 
ic traits such as genomic sequence can be 
analyzed directly in clinical specimens, with- 
out purification or isolation of the agent. 
Among the proven genotypic approaches for 
detecting and identifying previously unrecog- 
nized pathogens are broad-range polymerase 
chain reaction (PCR), representational differ- 
ence analysis (RDA), and expression library 
screening (2, 3). With broad-range PCR, one 
amplifies genetic loci whose sequences pro- 
vide reliable phylogenetic information about 
an infectious agent, using priming sites that 
are conserved among broad groups of agents. 
One of the most useful loci is the gene that 
encodes the small subunit ribosomal RNA. 
An extensive microbial ribosomal DNA 
(rDNA) sequence database enhances the use- 
fulness of this marker for diagnostic discrim- 
ination and resolution. For example, previ- 
ously unrecognized members of the bacterial 
domain can be identified with primers that 
recognize all bacterial small subunit rDNAs 
and amplify specific sequences (4-6); fami- 
lies of viruses can be explored with the 
broad-range PCR approach, using primers 
that are complimentary to genomic sequences 
conserved among all family members (7). 
The approach is also amenable to high- 
throughput methods. However, the advantag- 
es of broad-range PCR are partially offset by 
the problem of microbial DNA contamina- 
tion. Bacterial rDNA can be detected in clin- 
ical specimens from sterile sites of healthy 
individuals (for example, blood samples). 
Possible explanations include PCR reagent 
contamination, contamination of the speci- 
men during collection, and the presence of 
bacteria or their DNA within sterile sites 
despite the absence of apparent disease. Few 
investigations have addressed this third, but 
most intriguing, possibility. 
Other genotypic pathogen discovery ap- 
proaches complement the advantages and dis- 
advantages of broad-range PCR. RDA relies 
on subtractive hybridization to isolate rare 
genomic fragments (from an exogenous in- 
fectious agent) found in one (infected) spec- 
imen but not in an otherwise matched (unin- 
fected) specimen. With a subsequent PCR 
step, these rare fragments are enriched. With 
RDA, one addresses the problem of specimen 
contamination and endogenous microbial se- 
quences by using a matched specimen to 
reduce the presence of sequences that are 
common to the two specimens; however, 
unique genomic fragments from the infected 
specimen are enriched in a nonselective man- 
ner. These fragments may not provide specif- 
ic information about the putative pathogen; 
that is, not all genome sequences provide a 
useful view of phylogenetic history. With 
expression libraiy screening, pathogen-de- 
rived genomic fragments are identified from 
infected sites using host antisera, but only if 
the fragments encode antigenic products. 
Disease accompanied by autoreactive anti- 
bodies might pose additional problems. Some 
of the pathogens revealed with these ap- 
proaches are listed in Table 1. 
Any comprehensive pathogen detection 
effort faces additional challenges. In some 
instances, microorganisms cause disease 
from a distance. For example, toxic shock 
syndrome results from superantigen toxins 
released by Staphylococcus aureus or Strep- 
tococcus pyogenes strains that can be seques- 
tered at unsuspected anatomic sites, and bot- 
ulism usually occurs after ingestion of only 
the toxin. In other instances, infection ini- 
tiates an immunologic response that results in 
disease after the causative agent has been 
cleared from the host. For example, Campy- 
lobacterjejuni is proposed to cause Guillain- 
Baire syndrome, an acute inflammatory neu- 
1308 21 MAY 1999 VOL 284 SCIENCE www.sciencemag.org 
MICROBES, IMMUNITY, AND DISEASE 
ropathy, by eliciting cross-reactive antibodies 
to ganglioside that damage peripheral nerves 
weeks to months after intestinal infection (8). 
In all of these instances, nucleic acid from the 
pathogen would not be expected at sites of 
pathology or in the bloodstream. Of course, 
detection of nucleic acid does not indicate 
viability of the putative agent. 
To meet some of these challenges, one 
might turn instead to the host as a source of 
infection-specific genotypic information. In 
collaboration with Patrick Brown at Stanford 
University and Lou Staudt at the National 
Cancer Institute, we are collecting and ana- 
lyzing human gene expression responses to a 
wide variety of infectious agents and other 
noxious stimuli using microarrays containing 
complementary DNA (cDNA) for >15,000 
human genes. cDNA microarrays measure 
steady-state messenger RNA (mRNA) abun- 
dance in a miniaturized, massively parallel 
hybridization format. Comparisons of mRNA 
levels in multiple samples are accomplished 
with differential fluorescence labeling (9). 
Our hypothesis is that microbial pathogens 
induce stereotypic mRNA response profiles 
that can be used to distinguish among differ- 
ent infectious agents or different pathogenetic 
mechanisms (2, 10). The complex repertoire 
of potential human gene transcriptional re- 
sponses provides a far greater degree of spec- 
ificity than do the traditional markers of acute 
inflammation, such as cytokines and acute- 
phase proteins like C-reactive protein (11). 
The goal with this approach is to recognize 
diagnostic signatures in clinical specimens 
from unexplained illness that would reveal 
the etiologic agent and the time of initial host 
exposure. With this approach, infectious dis- 
eases might be classified in a radically differ- 
ent manner, on the basis of how a particular 
host "sees" an integrated collection of viru- 
lence mechanisms. 
Where to Look? 
A wide range of acute and chronic diseases 
and syndromes warrants broad cultivation- 
independent searches for microbial patho- 
gens. In short, there is a substantial amount of 
unexplained illness that resembles infectious 
disease. For example, most clinicians are fa- 
miliar with a scenario in which a previously 
healthy individual develops an acute life- 
threatening illness with signs of infection and 
negative diagnostic test results. One of the 
first efforts to identify and analyze such cases 
is the Unexplained Deaths project coordinat- 
ed by the Centers for Disease Control and 
Prevention (12). Our results from this ongo- 
ing project indicate that (i) unexplained death 
or critical illness occurs in 0.5 to 2.0 persons 
per 100,000 population in the United States 
per year, (ii) broad-range bacterial rDNA 
PCR reveals known disease-causing agents as 
a probable or definite pathogen in some cas- 
es, and (iii) little thought or attention has been 
directed at the selection and processing of 
clinical specimens that are appropriate for 
molecular pathogen discovery approaches. 
A number of chronic inflammatory syn- 
dromes also bear the hallmarks of microbial 
disease (some listed above) and are only now, 
belatedly, the subjects of broad-range molec- 
ular pathogen identification methods (13). 
Crohn's disease, for example, involves the 
entire intestinal wall in a relapsing-remitting, 
acute and chronic granulomatous inflamma- 
tory process (14). However, any effort to find 
a microbial etiologic agent for Crohn's dis- 
ease must address the issues of when and 
where it might be found in the course of this 
disease and how to deal with the complex, 
dense host-specific background of microor- 
ganisms within the intestines. Laser-capture 
microdissection (15) could complement all of 
the molecular approaches described above by 
focusing the search on suspect areas or cells 
within a tissue section and assisting with the 
selection of a more closely matched control 
sample (Fig. 1). 
The commensal microflora has been 
viewed as a source of specimen contamina- 
tion and occasional opportunistic pathogens, 
but it may play a more important role in 
health and disease than was once thought. 
The intestinal commensal flora is associated 
with the pathogenesis of inflammatory bowel 
disease such as Crohn's disease, with non- 
tropical sprue, and other disorders; it is also 
thought to play an essential role in intestinal 
epithelial differentiation. The endogenous 
flora of the mouth is associated with gingivi- 
tis, periodontitis, and systemic infections 
such as endocarditis. Yet, we are largely ig- 
norant of the composition of and the temporal 
and spatial dynamics within these microbial 
communities (16, 17). This ignorance results 
in part from an excessive reliance on micro- 
bial cultivation. A substantial proportion of hu- 
Table 1. Examples of human disease and associated microbial pathogens revealed during the past 15 
years. All of these infectious agents, except Helicobacter pylori, were first identified directly from clinical 
specimens using genotypic approaches. 
Disease Infectious agents Reference 
Peptic ulcer disease Helicobacter pylori (27) 
Non-A, non-B hepatitis Hepatitis C virus (28) 
Bacillary angiomatosis Bartonella henselae (5) 
Whipple's disease Tropheryma whippelii (29) 
Hantavirus pulmonary syndrome Sin Nombre virus (7) 
Kaposi's sarcoma Kaposi's sarcoma-associated herpesvirus (30) 
Plastic cap Glass slide 
Plastic 
,cap Transfer of 
Laser beam /Transfere 
Tissue section L..Ffilm on cells Tissuebaectio ,ckina_ lnd Individual 
Cells of ~~~~~~~~cell Cells of interest G\ i salmple Glass slide sml 
Fig. 1. A targeted broad-range rDNA PCR approach for pathogen discovery in Crohn's disease. 
Laser-capture microdissection allows one to isolate microscopic regions of tissue that have a 
greater likelihood of containing the pathogen (for example, granulomata or infected single cells). 
Granulomata are chronic inflammatory reactions that are frequently associated with persistent 
microorganisms or microbial antigen; they are found in tissues affected by Crohn's and other 
idiopathic diseases. Anatomic targeting is particularly important when there is gross microbial 
contamination of tissues, as in the intestinal wall from Crohn's disease. [Modified from Fig. 1 by 
Bonner et al. (15); histopathology courtesy of Donald Regula (Stanford University).] 
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man-associated microorganisms pends time as 
members of biofihms (for example, on the sur- 
face of teeth). As Costerton et al. point out, the 
sessile members of biofihms assume physiolog- 
ical states that render them resistant to cultiva- 
tion (18). With sensitive genotypic methods, 
one task will be to identify the previously un- 
recognized members of our endogenous muco- 
sal and cutaneous flora and then to track their 
possible translocation to other sites. For exam- 
ple, do chlamydia routinely traffic to vascular 
endothelia? Despite the recognized presence of 
archaea (methanogens) within the alimentary 
tract, why have no archaea been incriminated as 
pathogens? Are we not looking with appropri- 
ate methods in the right places? Another task 
will be to characterize quantitative and qualita- 
tive differences in community composition be- 
tween different anatomic niches and hosts and 
changes over time. 
Ecological concepts such as population 
heterogeneity and density may be critical in 
the transition from health to disease (for ex- 
ample, from plaque-associated gingivitis to 
adult-onset periodontitis). We will need new 
types of clinical measurements that reflect 
ecosystem health and stability (19). Our un- 
derstanding of endogenous microflora may 
also require reassessment. For example, un- 
suspected endosymbiotic rickettsia-like Wol- 
bachia species have been discovered in nem- 
atodes and have been found to play a role in 
host development (20). As we explore the 
details of the human genome and apply sen- 
sitive pathogen detection methods to human 
specimens, we should keep in mind the pos- 
sible clinical relevance of cryptic and not-so- 
cryptic human endogenous retroviruses (21). 
Microbes and Causation 
The application of new pathogen discovery 
methods is certain to alter our perspective on 
microbial disease causation. For example, im- 
provements in microbial detection and discrim- 
ination may generate data that challenge the 
traditional association of one microorganism 
with one diseased host. We currently accept the 
concept of polymicrobial disease causation in 
the setting of abscess formation; however, the 
same concept may apply to other types of dis- 
ease, including rheumatic or "autoimmune" dis- 
ease, and malignancy (17). Interaction and de- 
pendency between community members are es- 
sential features of microbial communities and 
biofilms (18). When a group of microbes cre- 
ates the conditions necessary for their collective 
success in a human niche or for the success of 
a newcomer, unanticipated consequences might 
include disruption of local epithelial cells, in- 
duction of a persistent virus, or perturbation of 
the local innate immune system (22) and, ulti- 
mately, disease. Gingivitis, inflammatory bow- 
el disease, and intestinal sprue may constitute 
disorders of the local endogenous microflora 
that result in impaired mucosal integrity and 
function. In these situations, the linkage be- 
tween microbe and disease is not linear and 
unidirectional. Genotype-based approaches that 
are quantitative, sensitive, and high throughput 
are needed. 
Other nontraditional concepts of microbi- 
al disease causation pose challenges for 
pathogen discovery methods. Molecular 
mimicry is a phenomenon involving the in- 
duction of self-directed immunity by micro- 
bial epitopes (which resemble host epitopes); 
this phenomenon may explain the role of 
streptococci in rheumatic heart disease, chla- 
mydia in coronary atherosclerosis (23), and 
C. jejuni with Guillain-Barre syndrome. The 
difficulty in detecting these pathogens at the 
site of pathology has been mentioned. As part 
of alternative strategies, one would like to use 
the host's immune responses to identify the 
antigenic stimulus. In addition to inducing 
self-immunity or immunity against the 
commensal flora, microbes are capable of 
inducing persistent changes in the local 
cytokine environment and in helper T cell 
expression profiles (24). These changes 
may protect the pathogen but may also 
result in damage to the host. Persistence of 
the microbial cell wall alone may be suffi- 
cient for these effects. Some of these mech- 
anisms may play a role in the etiology of 
Crohn's disease, in which most or all of the 
causative agent has largely disappeared by 
the time the diagnostic features of the dis- 
ease are recognized. In the absence of an 
ability to predict where the agent might be 
found at earlier time points, one must hope 
either for persistence of diagnostic micro- 
bial remnants such as sequence (Fig. 1) or 
specific host-derived signatures such as 
mRNA expression profiles. 
Proof of disease causation is a daunting 
goal when the putative etiologic factor cannot 
be isolated or purified and an appropriate 
disease model is not available. A world with- 
out the possibility of satisfying Koch's third 
postulate demands equivalent rigor in the at- 
tribution of causation. (The third postulate 
stipulates that disease be induced in a suitable 
host by inoculation with the isolated putative 
agent.) Most associations between microbe 
and disease are noncausal. Multiple corrobo- 
rating forms of circumstantial evidence must 
be sought with complementary alternative ap- 
proaches (25); plausibility can be addressed 
by investigating the molecular and cellular 
basis of pathology (26). All of these chal- 
lenges emphasize the need for well-con- 
trolled epidemiology, careful clinical and his- 
tologic observations, and increased attention 
to specimen collection and processing. One 
obvious payoff from the development and 
application of pathogen discovery approaches 
over the past 10 years has been the discovery 
of previously unrecognized disease-associat- 
ed agents. An equally important and less 
obvious payoff will be the reassessment of 
our relations with infectious agents and the 
way we view microbial disease causation. 
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